EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

DSG2+ Cancer Stem Cells Co‐Located With FAP+ Myofibroblasts in the Tumor Boundary That Determines the Efficacy of Immunotherapy in Non‐Small Cell Lung Cancer

Guangyu Fan, Le Tang, Tongji Xie, Mengwei Yang, Lin Li, Sheng Yang, Puyuan Xing, Xiaohong Han, Yuankai Shi iD

Advanced Science · 2026-04 · 13 (23)

DOI: 10.1002/advs.202514543 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Science, online erschienen am 15.02.2026. Verfasst von Guangyu Fan und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Beijing Key Laboratory of Key Technologies For Early Clinical Trial Evaluation of Innovative Drugs For Major Diseases…. Hauptthemen laut MEDLINE: Neoplastic Stem Cells, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Immunotherapy. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Science and Technology Major Project for Key New Drug Development, National High Level Hospital Clinical Research Funding.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lung cancer remains a leading cause of cancer‐related mortality owing to its aggressiveness and pronounced heterogeneity. Cancer stem cells (CSCs) have been implicated in tumor progression and therapeutic resistance; however, their transcriptional programs and spatial organization in non‐small cell lung cancer (NSCLC) are not fully characterized. Here, we integrated single‐cell RNA sequencing with spatial transcriptomics to systematically define CSC‐associated phenotype in NSCLC. Weighted gene co‐expression network analysis identified a 127‐gene CSC signature enriched for stemness‐related pathways, with DSG2 emerging as a dominant marker. Elevated DSG2 expression was associated with chemotherapy resistance and predicted response to EGFR tyrosine kinase inhibitors based on independent clinical proteomic datasets. Spatial mapping revealed preferential enrichment of DSG2+CSCs at tumor margins, where they co‐localized with FAP+myofibroblasts (myCAFs). Multiplex immunofluorescence demonstrated that FAP+myCAFs expressed MMP9 and MMP12, consistent with a microenvironment supportive of epithelial‐mesenchymal transition and CSC maintenance. Functional co‐culture assays showed that myCAFs enhanced CSC‐associated phenotypes in DSG2^high tumor cells in an MMP‐dependent manner. Collectively, these findings delineate a spatially organized DSG2+CSC–myCAF niche that contributes to therapeutic resistance in NSCLC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neoplastic Stem CellsCarcinoma, Non-Small-Cell LungLung NeoplasmsImmunotherapyMyofibroblastsGelatinasesMembrane ProteinsSerine EndopeptidasesHumansFibroblast Activation Protein AlphaEndopeptidasesTumor MicroenvironmentAnimals

Stichwörter der Autor:innen

EGFR‐TKI therapycancer stem cellsimmunotherapylung cancersingle‐cell RNA sequencingspatial transcriptomics

Substanzen

GelatinasesMembrane ProteinsSerine EndopeptidasesFibroblast Activation Protein AlphaEndopeptidases

Autor:innen und Institutionen

  • Department of Medical Oncology, Beijing Key Laboratory of Key Technologies For Early Clinical Trial Evaluation of Innovative Drugs For Major Diseases, National Cancer Center /National Clinical Research Center for Cancer…
  • Department of Pathology, National Cancer Center / National Clinical Research Center For Cancer / Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
  • Clinical Pharmacology Research Center, State Key Laboratory of Complex Severe and Rare Diseases, NMPA Key Laboratory For Clinical Research and Evaluation of Drug, Peking Union Medical College Hospital, Beijing Key Labor…

ORCID-Profile: Yuankai Shi

Förderung

  • National Science and Technology Major Project for Key New Drug Development
  • National High Level Hospital Clinical Research Funding

Zitieren

APA

Fan, G., Tang, L., Xie, T., Yang, M., Li, L., Yang, S., Xing, P., Han, X., & Shi, Y. (2026). DSG2+ Cancer Stem Cells Co‐Located With FAP+ Myofibroblasts in the Tumor Boundary That Determines the Efficacy of Immunotherapy in Non‐Small Cell Lung Cancer. Advanced Science, 13(23). https://doi.org/10.1002/advs.202514543

Vancouver

Fan G, Tang L, Xie T, Yang M, Li L, Yang S, et al. DSG2+ Cancer Stem Cells Co‐Located With FAP+ Myofibroblasts in the Tumor Boundary That Determines the Efficacy of Immunotherapy in Non‐Small Cell Lung Cancer. Advanced Science. 2026;13(23). doi:10.1002/advs.202514543

BibTeX
@article{Fan2026,
  author = {Fan, Guangyu and Tang, Le and Xie, Tongji and Yang, Mengwei and Li, Lin and Yang, Sheng and Xing, Puyuan and Han, Xiaohong and Shi, Yuankai},
  title = {DSG2+ Cancer Stem Cells Co‐Located With FAP+ Myofibroblasts in the Tumor Boundary That Determines the Efficacy of Immunotherapy in Non‐Small Cell Lung Cancer},
  journal = {Advanced Science},
  year = {2026},
  volume = {13},
  number = {23},
  doi = {10.1002/advs.202514543}
}
Kostenlos starten →